dc.creator | Salguero-Aranda, Carmen | es |
dc.creator | Olmedo Pelayo, Joaquín | es |
dc.creator | Álava Casado, Enrique de | es |
dc.creator | Amaral, Ana Teresa | es |
dc.creator | Díaz-Martín, Juan | es |
dc.date.accessioned | 2023-03-31T16:33:24Z | |
dc.date.available | 2023-03-31T16:33:24Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Salguero-Aranda, C., Olmedo Pelayo, J., Álava Casado, E.d., Amaral, A.T. y Díaz-Martín, J. (2022). Genetic alterations and deregulation of hippo pathway as a pathogenetic mechanism in bone and soft tissue sarcoma. Cancers, 14 (24), 6211. https://doi.org/10.3390/cancers14246211. | |
dc.identifier.issn | 2072-6694 | es |
dc.identifier.uri | https://hdl.handle.net/11441/143845 | |
dc.description.abstract | The Hippo pathway is an evolutionarily conserved modulator of developmental biology
with a key role in tissue and organ size regulation under homeostatic conditions. Like other signaling
pathways with a significant role in embryonic development, the deregulation of Hippo signaling
contributes to oncogenesis. Central to the Hippo pathway is a conserved cascade of adaptor proteins
and inhibitory kinases that converge and regulate the activity of the oncoproteins YAP and TAZ,
the final transducers of the pathway. Elevated levels and aberrant activation of YAP and TAZ have
been described in many cancers. Though most of the studies describe their pervasive activation
in epithelial neoplasms, there is increasing evidence pointing out its relevance in mesenchymal
malignancies as well. Interestingly, somatic or germline mutations in genes of the Hippo pathway
are scarce compared to other signaling pathways that are frequently disrupted in cancer. However,
in the case of sarcomas, several examples of genetic alteration of Hippo members, including gene
fusions, have been described during the last few years. Here, we review the current knowledge of
Hippo pathway implication in sarcoma, describing mechanistic hints recently reported in specific
histological entities and how these alterations represent an opportunity for targeted therapy in this
heterogeneous group of neoplasm. | es |
dc.description.sponsorship | Consejería de Salud y Familias, Junta de Andalucía | es |
dc.format | application/pdf | es |
dc.format.extent | 30 p. | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | Cancers, 14 (24), 6211. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Hippo pathway | es |
dc.subject | YAP | es |
dc.subject | TAZ | es |
dc.subject | Sarcoma | es |
dc.subject | Gene fusion | es |
dc.title | Genetic alterations and deregulation of hippo pathway as a pathogenetic mechanism in bone and soft tissue sarcoma | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Citología e Histología Normal y Patológica | es |
dc.relation.projectID | PE-0186-2018 | es |
dc.relation.publisherversion | https://www.mdpi.com/2072-6694/14/24/6211 | es |
dc.identifier.doi | 10.3390/cancers14246211 | es |
dc.journaltitle | Cancers | es |
dc.publication.volumen | 14 | es |
dc.publication.issue | 24 | es |
dc.publication.initialPage | 6211 | es |